CU20170086A7 - Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 - Google Patents

Pirazolpiridinaminas como inhibidores de mknk1 y mknk2

Info

Publication number
CU20170086A7
CU20170086A7 CUP2017000086A CU20170086A CU20170086A7 CU 20170086 A7 CU20170086 A7 CU 20170086A7 CU P2017000086 A CUP2017000086 A CU P2017000086A CU 20170086 A CU20170086 A CU 20170086A CU 20170086 A7 CU20170086 A7 CU 20170086A7
Authority
CU
Cuba
Prior art keywords
compounds
disease
pirazolpiridinamins
mknk1
mknk2
Prior art date
Application number
CUP2017000086A
Other languages
English (en)
Inventor
Dra Anja Giese
Dr Keith Graham
Dr Georg Kettschau
Dr Ulrich Klar
Dr Julien Lefranc
Dr Philip Lienau
Dra Kirstin Petersen
Dra Nicole Schmidt
Dr Detlev Sülzle
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20170086A7 publication Critical patent/CU20170086A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>Compuestos de pirazolpiridinamina sustituida de fórmula general (I) según se los describe y define<br /> aquí, métodos para preparar dichos compuestos, compuestos intermediarios útiles para preparar dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden a dichos compuestos y el uso de dichos compuestos para elaborar una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad, en particular de un trastorno hiperproliferativo y/o de angiogénesis, enfermedad inflamatoria y enfermedad asociada con dolor inflamatorio, como único agente o en combinación con otros ingredientes activos.</p>
CUP2017000086A 2014-12-19 2015-12-14 Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 CU20170086A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199096 2014-12-19
EP15187501 2015-09-29
PCT/EP2015/079587 WO2016096721A1 (en) 2014-12-19 2015-12-14 Pyrazolopyridinamines as mknk1 and mknk2 inhibitors

Publications (1)

Publication Number Publication Date
CU20170086A7 true CU20170086A7 (es) 2017-11-07

Family

ID=54884024

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2017000086A CU20170086A7 (es) 2014-12-19 2015-12-14 Pirazolpiridinaminas como inhibidores de mknk1 y mknk2

Country Status (27)

Country Link
US (1) US10487092B2 (es)
EP (1) EP3233866B1 (es)
JP (1) JP2018501250A (es)
KR (1) KR20170095985A (es)
CN (1) CN107250138A (es)
AU (1) AU2015366417A1 (es)
BR (1) BR112017013148A2 (es)
CA (1) CA2971242A1 (es)
CL (1) CL2017001615A1 (es)
CO (1) CO2017005968A2 (es)
CR (1) CR20170264A (es)
CU (1) CU20170086A7 (es)
DO (1) DOP2017000146A (es)
EA (1) EA201791363A1 (es)
EC (1) ECSP17038893A (es)
GT (1) GT201700138A (es)
IL (1) IL252686A0 (es)
MX (1) MX2017008161A (es)
NI (1) NI201700078A (es)
PE (1) PE20171104A1 (es)
PH (1) PH12017501133A1 (es)
SG (1) SG11201704916TA (es)
SV (1) SV2017005466A (es)
TN (1) TN2017000258A1 (es)
TW (1) TW201625648A (es)
UY (1) UY36460A (es)
WO (1) WO2016096721A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
WO2017081003A1 (en) * 2015-11-12 2017-05-18 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyridinamines
KR20190117013A (ko) 2017-02-14 2019-10-15 이펙터 테라퓨틱스, 인크. 피페리딘-치환된 Mnk 억제제 및 그와 관련된 방법
EP3870178A4 (en) 2018-10-24 2022-08-03 Effector Therapeutics Inc. CRYSTALLINE FORMS OF MNK INHIBITORS
CN111803476A (zh) * 2020-08-14 2020-10-23 华中科技大学协和深圳医院 芬戈莫德用于抑制革兰阳性细菌活性的用途
JP2023541601A (ja) 2020-09-10 2023-10-03 プレシリックス・ナームローゼ・ベンノートシヤープ Ｆａｐに対する抗体フラグメント
US20230000986A1 (en) * 2021-07-01 2023-01-05 Board Of Regents, The University Of Texas System Mnk inhibitors and eif4e phosphorylation modulation to treat inflammatory pain in the aged
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
DE602004003952T2 (de) * 2003-07-24 2007-11-08 Bayer Pharmaceuticals Corp., West Haven Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
EP1799653B1 (en) * 2004-08-20 2013-03-20 Bayer Intellectual Property GmbH Condensed thienopyrimidine derivatives for the treatment of cancer
WO2012097013A1 (en) * 2011-01-10 2012-07-19 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP2852596B1 (en) * 2012-05-21 2016-06-22 Bayer Pharma Aktiengesellschaft Thienopyrimidines
ES2592404T3 (es) * 2012-05-21 2016-11-30 Bayer Pharma Aktiengesellschaft Benzotienopirimidinas sustituidas
WO2014074657A1 (en) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
CN105189518A (zh) 2013-02-01 2015-12-23 拜耳制药股份公司 取代的噻吩并吡啶和其药物用途

Also Published As

Publication number Publication date
TW201625648A (zh) 2016-07-16
JP2018501250A (ja) 2018-01-18
KR20170095985A (ko) 2017-08-23
BR112017013148A2 (pt) 2019-11-19
CN107250138A (zh) 2017-10-13
EP3233866A1 (en) 2017-10-25
CO2017005968A2 (es) 2017-10-20
IL252686A0 (en) 2017-08-31
DOP2017000146A (es) 2017-07-31
NI201700078A (es) 2017-09-22
US20180162877A1 (en) 2018-06-14
CL2017001615A1 (es) 2018-03-16
PE20171104A1 (es) 2017-08-07
ECSP17038893A (es) 2017-07-31
MX2017008161A (es) 2017-09-18
EP3233866B1 (en) 2021-04-21
CA2971242A1 (en) 2016-06-23
CR20170264A (es) 2017-07-21
TN2017000258A1 (en) 2018-10-19
UY36460A (es) 2016-07-29
WO2016096721A1 (en) 2016-06-23
US10487092B2 (en) 2019-11-26
GT201700138A (es) 2018-12-06
SV2017005466A (es) 2018-10-02
PH12017501133A1 (en) 2017-11-27
AU2015366417A1 (en) 2017-06-29
EA201791363A1 (ru) 2018-01-31
SG11201704916TA (en) 2017-07-28

Similar Documents

Publication Publication Date Title
ECSP17007538A (es) 2-(morfolin-4-il)-1,7-naftiridinas
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
CU20170086A7 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
UY33598A (es) Imidazopiridazinas sustituidas
ECSP14013231A (es) Imidazopiridazinas sustituidas con amino
CU20160072A7 (es) Tienopirimidinas como inhibidores mknk1 y mknk2
DOP2016000253A (es) Nuevos compuestos
NI201600006A (es) Pirazolo-piridinaminas sustituidas
NI201500118A (es) Imidazopiridazinas sustituidas
DOP2016000268A (es) Compuestos de azol amido–sustituidos como inhibidores de tnks1 y/o tnks2
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CU20160139A7 (es) Benzamidas y anilidas sustituidas en calidad de inhibidores de las vías de de señalización wnt, las composiciones y combinaciones farmacéuticas que las comprenden, y los compuestos intermediarios útiles para preparar estos compuestos
UY37444A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso
UY36983A (es) Pirazolopiridinaminas sustituidas
UY37032A (es) Compuestos de heteroarilbenzimidazol
UY34630A (es) Imidazopiridazinas sustituidas con amino
AR094934A1 (es) Imidazopiridazinas sustituidas